Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opening Session Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Nov
13
Today In Oncology
Metastatic Uveal Melanoma Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
American Cancer Society Updates Prostate Cancer Screening Guideline
Childhood Cancers Survival Gains Reveal Progress and Persistent Disparities
Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo